FIGURE 4 from Lung Fibroblasts Take up Breast Cancer Cell-derived Extracellular Vesicles Partially Through MEK2-dependent Macropinocytosis

• DOI: 10.1158/2767-9764.25041206.v1
• Publication Date: 2024-01-22T14:20:20Z
• Authors: Yuhao Wan; Yue Zhao; Minghui Cao; Jingyi Wang; Sheila V. Tran; Zhixuan Song; Brent W. Hsueh; Shizhen Emily Wang
• Keywords: Trametinib

<p>Pathway inhibitors Trametinib and Copanlisib inhibit the uptake effect of EVs from various breast cancer cells. <b>A,</b> Western blots lung fibroblasts treated with 200 nmol/L or 10 µg/mL EV for 24 hours. <b>B,</b> qRT-PCR–determined mRNA levels S100A4 FN1 without MDA-MB-231 treatment 48 were added together when indicated. Data normalized to GAPDH. <b>C,</b> Lung pretreated (200 mmol/L) hours before Lck-GFP–labeled derived 4T1 MDA-MB-468 cells incubated 6 was assessed compared DMSO-treated (No drug) control group. <b>D,</b> NIH3T3 added. are represented as mean ± SD (<i>n</i> = 3 wells). **, <i>P</i> < 0.01; ***, 0.001.</p>